Methods for handling uncertainty within pharmaceutical funding decisions

International Journal of Systems Science

Volumn 45, Issue 1, 2014, Pages 60-68

  Stevenson, Matt ^a   Tappenden, Paul ^a   Squires, Hazel ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

health economics; mathematical modelling; uncertain data; value of information

Indexed keywords

DECISION MAKING UNDER UNCERTAINTY; ECONOMIC EVALUATIONS; HEALTH ECONOMIC EVALUATIONS; HEALTH ECONOMICS; PARAMETER UNCERTAINTY; STRUCTURAL UNCERTAINTY; UNCERTAIN DATAS; VALUE OF INFORMATION;

ECONOMIC ANALYSIS; INVESTMENTS; MATHEMATICAL MODELS;

HEALTH CARE;

EID: 84884829218     PISSN: 00207721     EISSN: 14645319     Source Type: Journal    
DOI: 10.1080/00207721.2012.723056     Document Type: Article

References (42)

1. Ades, AE, Lu, G, and, Claxton, K. 2004. Expected Values of Sample Information Calculation in Medical Decision Making. Medical Decision Making, 24: 207-227. (Pubitemid 38391940)
2. Bojke, L, Claxton, K, Sculpher, M, and, Palmer, S. 2009. Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods. Value in Health, 12: 739-749.
3. Brazier, J, and, Roberts, J. 2004. The Estimation of a Preference-based Index from the SF-12. Medical Care, 42: 851-859.
4. Brazier, J, Roberts, J, and, Deverill, M. 2002. The Estimation of a Preference-based Single Index Measure for Health from the SF-36. Journal of Health Economics, 21: 271-292. (Pubitemid 34143147)
5. Brennan, A, and, Kharroubi, SA. 2007. Efficient Computation of Partial Expected Value of Sample Information Using Bayesian Approximation. Journal of Health Economics, 26: 122-148. (Pubitemid 44908721)
6. Briggs, A, Claxton, K, and, Sculpher, M. 2006. Decision Modelling for Health Economic Evaluation, Oxford: Oxford University Press.
7. Caldwell, DM, Ades, AE, and, Higgins, JP. 2005. Simultaneous Comparison of Multiple Treatments: Combining Direct and Indirect Evidence. British Medical Journal, 331: 897-900. (Pubitemid 41502718)
8. Chilcott, J, Tappenden, P, Rawdin, A, Johnson, M, Kaltenthaler, E, Papaioannou, D, and, Shippam, A. 2010. Avoiding and Identifying Errors in Health Technology Assessment Models. Health Technology Assessment, 14: 1-79.
9. Claxton, K, and, Posnett, J. 1996. An Economic Approach to Clinical Trial Design and Research Priority-setting. Health Economics, 5: 513-524.
10. Claxton, K, Sculpher, M, McCabe, C, Briggs, A, Akehurst, R, Buxton, M, Brazier, J, and, O'Hagan, T. 2005. Probabilistic Sensitivity Analysis for NICE Technology Assessment: Not an Optional Extra. Health Economics, 14: 339-347. (Pubitemid 40514748)
11. Dolan, P. 1997. Modelling Valuations for EuroQol Health States. Medical Care, 35: 1095-1108. (Pubitemid 127453463)
12. Doubilet, P, Begg, CB, Weinstein, MC, Braun, P, and, McNeil, BJ. 1985. Probabilistic Sensitivity Analysis Using Monte Carlo Simulation: A Practical Approach. Medical Decision Making, 5: 157-177. (Pubitemid 16130640)
13. Feeny, D, Furlong, W, Torrance, GW, Goldsmith, CH, Zhu, Z, DePauw, S, Denton, M, and, Boyle, M. 2002. Multi-attribute and Single-attribute Utility Functions for the Health Utilities Index Mark 3 System. Medical Care, 40: 113-128.
14. Felli, JC, and, Hazen, GB. 1998. Sensitivity Analysis and the Expected Value of Perfect Information. Medical Decision Making, 18: 95-109. (Pubitemid 28041646)
15. Fenwick, E, Claxton, K, and, Sculpher, M. 2001. Representing Uncertainty: The Role of Cost-effectiveness Acceptability Curves. Health Economics, 10: 779-787. (Pubitemid 34041389)
16. Hoeting, J, Madigan, D, Raftery, A, and, Volinsky, C. 1999. Bayesian Model Averaging: A Tutorial. Statistical Science, 14: 382-417.
17. Inglehart, DL. 1975. Simulating Stable Stochastic Systems, V: Comparison of Ratio Estimators. Naval Research Logistics Quarterly, 22: 553-565.
18. Kennedy, M, and, OHagan, A. 2001. Bayesian Calibration of Computer Models (with Discussion). Journal of the Royal Statistical Society, Series B, 63: 425-464. (Pubitemid 33305774)
19. Kind, P. Hardman, G., and Macran, S. (1999), UK Population Norms for EQ-5D, Centre for Health Economics, Discussion Paper 172, The University of York. http://www.york.ac.uk/media/che/documents/papers/discussionpapers/ CHE%20Discussion%20Paper%20172.pdf
20. Latimer, N. and Trowman, R. (2010), Controlling for Treatment Switching in NICE Technology Appraisals, in Health Technology Assessment International Conference. http://www.htai.org/fileadmin/HTAi-Files/Conferences/2010/OP2- 2%20Nicolas%20Latimer.pdf
21. Law, A. 2007. Simulation Modelling and Analysis, 4th, Singapore: McGraw-Hill.
22. Lu, G, and, Ades, A. 2006. Assessing Evidence Consistency in Mixed Treatment Comparisons. Journal of the American Statistical Association, 101: 447-459. (Pubitemid 43972289)
23. Madan, J, Stevenson, MD, Ades, T, Cooper, KL, Whyte, S, and, Akehurst, R. 2011. Consistency between Direct Trial Evidence and Bayesian Mixed Treatment Comparison: Is Head-to-head Evidence Always More Reliable?. Value in Health, 14: 953-960.
24. Michaels, JA, Campbell, B, King, BM, Palfreyman, SJ, Shackley, P, and, Stevenson, MD. 2009. A Prospective Randomised Controlled Trial and Economic Modelling of Anti-microbial Silver Dressing Bandages versus Non-adherent Control Dressings for Venous Leg Ulcers: The Vulcan Trial. Health Technology Assessment, 13: 1-138.
25. Morgan, MG, and, Henrion, M. 1990. Uncertainty, Cambridge: Cambridge University Press.
26. National Institute for Health and Clinical Excellence (NICE) (2004), Guide to the Methods of Technology Appraisals. http://www.nice.org.uk/niceMedia/ pdf/TAP-Methods.pdf
27. NICE (2008), Guide to the Methods of Technology Appraisals. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
28. NICE (2009), Appraising Life-extending, End of Life Treatments. http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf
29. NICE (2011), Discounting of Health Benefits in Special Circumstances. http://www.nice.org.uk/media/955/4F/Clarification-to-section-5. 6-of-the-Guide-to-Methods-of-Technology-Appraisals.pdf
30. OHagan, A, Stevenson, M, and, Madan, J. 2007. Monte Carlo Probabilistic Sensitivity Analysis for Patient Level Simulation Models: Efficient Estimation of Mean and Variance Using ANOVA. Health Economics, 16: 1009-1023. (Pubitemid 47534730)
31. Robins, JM, and, Finkelstein, DM. 2000. Correcting for Non-compliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log-rank Tests. Biometrics, 56: 779-788.
32. Robins, JM, and, Tsiatis, AA. 1991. Correcting for Non-compliance in Randomized Trials Using Rank Preserving Structural Failure Time Models. Communications in Statistics-Theory and Methods, 20: 2609-2631.
33. Speigelhalter, D, Myles, J, Jones, D, and, Abrams, K. 1999. An Introduction to Bayesian Methods in Health Technology Assessment. British Medical Journal, 319: 508-512.
34. Stevenson, MD, and, Lloyd Jones, MM. 2011. The Cost Effectiveness of an RCT Comparing Alendronate with Vitamin K 1. Medical Decision Making, 31: 43-52.
35. Stevenson, MD, Oakley, J, and, Chilcott, JB. 2004. Gaussian Process Modelling in Conjunction with Individual Patient Simulation Modelling: A Case Study Describing the Calculation of Cost-effectiveness Ratios for the Treatment of Osteoporosis. Medical Decision Making, 24: 89-100. (Pubitemid 38116861)
36. Stevenson, MD, Oakley, JE, Lloyd Jones, M, Brennan, A, Compston, JE, McCloskey, EV, and, Selby, PL. 2009. The Cost-effectiveness of an RCT to Establish Whether 5 or 10 Years of Bisphosphonate Treatment is the Better Duration for Women with a Prior Fracture. Medical Decision Making, 29: 678-689.
37. Stevenson, MD, Simpson, EL, Rawdin, AC, and, Papaioannou, DE. 2010. A Review of Discrete Event Simulation in National Coordinating Centre for Health Technology Assessment Funded Work and a Case Study Exploring the Cost-effectiveness of Testing for Thrombophilia in Patients Presenting with an Initial Idiopathic Venous Thromboembolism. Journal of Simulation, 4: 14-423.
38. Strong, M, Oakley, JE, and, Chilcott, J. 2012. Managing Structural Uncertainty in Health Economic Decision Models: A Discrepancy Approach. Journal of the Royal Statistical Society Series C (Applied Statistics), 61: 25-45.
39. Tappenden, P, Chilcott, JB, Brennan, A, and, Pilgrim, H. 2009. Systematic Review of Economic Evidence for the Detection, Diagnosis, Treatment and Follow-up of Colorectal Cancer in the UK. International Journal of Technology Assessment in Health Care, 25: 470-478.
40. Tappenden, P, Chilcott, JB, Eggington, S, Oakley, J, and, McCabe, C. 2004. Methods for Expected Value of Information Analysis in Complex Health Economic Models: Developments on the Health Economics of Interferon-β and Glatiramer Acetate for Multiple Sclerosis. Health Technology Assessment, 8: 1-92.
41. Tosh, J. and Wailoo, A. (2008), Review of Software for Decision Modelling. http://www.nicedsu.org.uk/PDFs%20of%20reports/softwarereport-final. pdf
42. Weinstein, MC, and, Statson, WB. 1977. Foundations of Cost Effectiveness Analysis for Health and Medical Practices. The New England Journal of Medicine, 296: 716-721. (Pubitemid 8066534)